Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial

Journal:
The Lancet Diabetes & Endocrinology
Published:
DOI:
10.1016/s2213-8587(25)00196-2
Affiliations:
21
Authors:
31
Go to article
Institutions Authors Share
Sciwind Biosciences Co., Ltd., China
12.000000
12.000000
 0.39
Zhongshan Hospital, Fudan University, China
2.000000
 0.06
Second Affiliated Hospital of Shanxi Medical University, SXMU, China
1.000000
 0.03
Jinan Central Hospital, China
1.000000
 0.03
Shengjing Hospital of China Medical University, China
1.000000
 0.03
The First Hospital of Qiqihar, China
1.000000
 0.03
Peking University Binhai Hospital, China
1.000000
 0.03
Affiliated Hospital of SDMPU, China
1.000000
 0.03
CNPC Central Hospital, China
1.000000
 0.03
Fourth Affiliated Hospital, HMU, China
1.000000
 0.03
Pingxiang Second People's Hospital, China
1.000000
 0.03
Tonghua Central Hospital, China
1.000000
 0.03
Jining First People's Hospital, China
1.000000
 0.03
Shijiazhuang People's Hospital, China
1.000000
 0.03
Wuhan Third Hospital, China
1.000000
 0.03
Heilongjiang Provincial Hospital, China
1.000000
 0.03
Second Affiliated Hospital, ZZU, China
1.000000
 0.03
Affiliated Hospital, XZMC, China
1.000000
 0.03
Handan First Hospital, China
1.000000
 0.03
Interested in Pharmacology and Pharmaceutical Sciences?